Prostate cancer cells show elevated urokinase receptor in a mouse model of metastasis

Cancer Cell International

Volumn 6, Issue , 2006, Pages

  Sehgal, Inder ^a   Foster, Timothy P ^a   Francis, Joseph ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOIKIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CELL SUBPOPULATION; CELL SUSPENSION; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION;

EID: 33748626267     PISSN: 14752867     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-6-21     Document Type: Article

References (27)

1. Nicolson GL: Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 1988, 7:143-188.
2. Albini A, Benelli R, Noonan DM, Brigati C: The "chemoinvasion assay": a tool to study tumor and endothelial cell invasion of basement membranes. Int J Dev Biol 2004, 48:563-71.
3. Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, Glinsky GV: Increased Expression of Apoptosis Inhibitor Protein XIAP Contributes to Anoikis Resistance of Circulating Human Prostate Cancer Metastasis Precursor Cells. Cancer Research 2005, 65:2378-2386.
4. Fernandez Y, Espana L, Manas S, Fabra A, Sierra A: Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance. Cell Death Differ 2000, 7:350-9.
5. Condon MS: The role of the stromal microenvironment in prostate cancer. Seminars in Cancer Biology 2004, 15:132-137.
6. Stewart DA, Cooper CR, Sikes RA: Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reprod Biol Endocrinol 2004, 2:2.
7. Sidenius N, Blasi F: The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003, 22:205-22.
8. Duffy MJ: Urokinase plasminogen activator and its inhibitor PAI-1 as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002, 48:1194-1197.
9. Alfano D, Franco P, Vocca I, Gambi N, Pisa V, Mancini A, Caputi M, Carriero MV, Iaccarino I, Stoppelli MP: The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005, 93:205-211.
10. Alfano D, Iaccarino I, Stoppelli MP: Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem 2006, 281:17758-67.
11. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S: Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999, 39:123-9.
12. McCabe NP, Angwafo FF 3rd, Zaher A, Selman SH, Kouinche A, Jankun J: Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol Reports 2000, 7:879-882.
13. Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brunner N, Dano K, Hoyer-Hansen G, Lilja H: Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006, 52:838-44.
14. Gavrilov D, Kenzior O, Evans M, Calaluce R, Folk WR: Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer 2001, 37:1033-1040.
15. Usher PA, Thomsen OF, Iversen P, Johnsen M, Brunner N, Hoyer-Hansen G, Andreasen P, Dano K, Nielsen BS: Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 2005, 113:870-80.
16. Heiss MM, Simon EH, Beyer BC, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW, Allgayer H: Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002, 20:2005-2016.
17. Margheri F, D'Alessio S, Serrati S, Pucci M, Annunziato, F, Cosmi L, Liotta F, Angeli R, Angelucci A, Gravina GL, Rucci N, Bologna M, Teti A, Monia B, Fibbi G, Del Rosso M: Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Therapy 2005, 12:702-714.
18. Rabbani SA, Gladu J: Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Research 2002, 62:2390-2397.
19. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005, 280:36529-36540.
20. Chu JH, Sun ZY, Meng XL, Wu JH, He GL, Liu GM, Jiang XR: Differential metastasis-associated gene analysis of prostate carcinoma cells derived from primary tumor and spontaneous lymphatic metastasis in nude mice with orthotopic implantation of PC-3M cells. Cancer Letters 2006, 233:79-88.
21. Frisch SM, Ruoslahti E: Integrins and anoikis. Curr Opin Cell Biol 1997, 9:701-706.
22. Forbes K, Gillette KM, Kelly L, Sehgal I: Urokinase Plasminogen Activator Receptor (uPAR) is increased in re-metastasized prostate cancer cells. World Journal of Urology 2004, 22:67-71.
23. Ruoslahti E, Reed JC: Anchorage dependence, integrins, and apoptosis. Cell 1994, 77:477-478.
24. Rennebeck G, Martelli M, Kyprianou N: Anoikis and survival connections in the tumor microenvironment: Is there a role in prostate cancer metastasis? Cancer Research 2005, 65:11230-11235.
25. Li L, Ren CH, Tahir SA, Ren C, Thompson TC: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2203, 23:9389-404.
26. Nguyen DHD, Hussaini IM, Gonias SL: Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998, 273:8502-8507.
27. Barnathan ES, Kuo A, Kariko K, Rosenfeld L, Murray SC, Behrendt N, Ronne E, Weiner D, Henkin J, Cines DB: Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. Blood 1990, 76:1795-806.